The effect of tailored consumer medicine information on patients with type 2 diabetes mellitus: A randomised controlled interventional study. Issue 8 (9th June 2020)

• Record Type: Journal Article
• Authors: Munsour, Emad E.; Awaisu, Ahmed; Hassali, Mohamed Azmi A.; Abdoun, Enas; Dabbous, Zeinab; Zahran, Noran; Ali, Hamda
• Is Part Of: International journal of clinical practice. Volume 74:Issue 8(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-09
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.13527
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Introduction: In patients with diabetes, better health communication is associated with better health outcomes including medication adherence and glycaemic control. The conventional patient information leaflet does not consider the cultural and behavioral perspectives of diverse patient populations. Consumer medicine information (CMI) is a written information about the prescription drugs developed by organisations or individuals other than a drug manufacturer that is intended for distribution to consumers at the time of medication dispensing. Objective: This study aimed to evaluate the impact of CMI on medication adherence and glycaemic control among patients with type 2 diabetes in Qatar. Methods: We developed and customised CMI for all the anti‐diabetic medications used in Qatar. A randomised controlled trial in which the intervention group patients (n = 66) received the customised CMI with usual care, while the control group patients (n = 74) received usual care only, was conducted. Self‐reported medication adherence and haemoglobin A1c (HbA1c ) were the primary outcome measures. Glycaemic control and medication adherence parameters were measured at baseline, 3 months, and 6 months in both groups. Medication adherence was measured using the 8‐item Morisky Medication Adherence Scale (MMAS‐8). Results: Although the addition of CMI resulted in better glycaemic control, this did not reach statistical significance, possibly because of the short‐term follow‐up. The median MMAS‐8 score improved from baseline (6.6 [IQR = 1.5]) to 6‐month follow‐up (7.0 [IQR = 1.00]) in the intervention group. In addition, there was a statistically significant difference between the intervention and the control groups in terms of MMAS‐8 score at the third visit (7.0 [IQR = 1.0]) vs 6.5 (IQR = 1.25; P ‐value = .010). Conclusion: CMI for anti‐diabetic medications when added to usual care has the potential to improve medication adherence and glycaemic control among patients with type 2 diabetes. Therefore, providing better health communication and CMI to patients with diabetes is recommended.